Tocagen (TOCA) Tops Q1 EPS by 27c

Tocagen (NASDAQ: TOCA) reported Q1 EPS of ($0.74), $0.27 better than the analyst estimate of ($1.01).

"We had a strong start to the year with excellent progress on multiple fronts related to our Phase 3 Toca 5 trial of Toca 511 & Toca FC in patients with recurrent high grade glioma and potential commercial launch," said Marty Duvall, chief executive officer of Tocagen. "We ended the quarter well capitalized to fund operations into 2020 and look forward to the pending interim analysis of the Toca 5 trial this quarter and the final analysis by the end of the year."

For earnings history and earnings-related data on Tocagen (TOCA) click here.

You May Also Be Interested In

• Faraday Future signs robotics distributor deal, plans partner event
• Home Depot expands executive roles, grants $500K in restricted stock
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics